Obinutuzumab: all 213 studies that test it
Page 2 of 3. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02406742Phase 1/2Results posted
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedNCT02391545Phase 1/2Results posted
- A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT02320487Phase 2Results posted
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.CompletedNCT02315768Phase 1/2Results posted
- A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaCompletedNCT02257567Phase 1/2Results posted
- Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT02225275Phase 2Results posted
- A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT02071225Phase 2Results posted
- A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLCompletedNCT02055820Phase 1/2Results posted
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)CompletedNCT02053610Phase 3Results posted
- CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)CompletedNCT01998880Phase 3Results posted
- Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01995669Phase 1/2Results posted
- A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaCompletedNCT01992653Phase 1/2Results posted
- A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic LeukemiaCompletedNCT01905943Phase 3Results posted
- Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's LymphomaTerminatedNCT01889797Phase 2Results posted
- An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT01868893Phase 2Results posted
- A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01691898Phase 1/2Results posted
- A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant DiseaseCompletedNCT01680991Phase 1Results posted
- A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)CompletedNCT01414855Phase 2Results posted
- A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)CompletedNCT01414205Phase 2Results posted
- A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)CompletedNCT01332968Phase 3Results posted
- A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)TerminatedNCT01287741Phase 3Results posted
- A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)CompletedNCT01059630Phase 3Results posted
- CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)CompletedNCT01010061Phase 3Results posted
- GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's LymphomaCompletedNCT00576758Phase 2Results posted
- A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)CompletedNCT00517530Phase 1/2Results posted
- Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaSuspendedNCT06922604Phase 1
- Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
- Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
- REmission in Membranous Nephropathy International Trial (REMIT)WithdrawnNCT06120673Phase 3
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedNCT05896163Phase 1/2
- Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial CancersWithdrawnNCT05894447Phase 1
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaSuspendedNCT05861050Phase 1/2
- GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
- Glofit and Obin in Follicular Lymphoma and Marginal Zone LymphomaActive, not recruitingNCT05783596Phase 2
- Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabActive, not recruitingNCT05650723Phase 2
- A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor BurdenActive, not recruitingNCT05387616Phase 2
- Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05057494Phase 3
- Obinutuzumab in Primary MNCompletedNCT05050214Phase 2
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus ErythematosusActive, not recruitingNCT04963296Phase 3
- Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyActive, not recruitingNCT04962126Phase 2
- A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;CompletedNCT04939363Phase 2
- Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"TerminatedNCT04920968Phase 2
- CAR-T Followed by Bispecific AntibodiesActive, not recruitingNCT04889716Phase 2
- Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-TreatmentCompletedNCT04826003Phase 1
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLActive, not recruitingNCT04722172Phase 2
- A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04657302Phase 1
- CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.Active, not recruitingNCT04639362Phase 2
- A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous NephropathyActive, not recruitingNCT04629248Phase 3
- Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Active, not recruitingNCT04608318Phase 3
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
- Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT04505254Phase 2
- Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT04450173Phase 2
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT04447768Phase 2
- A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
- ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationActive, not recruitingNCT04082897Phase 2
- Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS LymphomaTerminatedNCT04073147Phase 1
- A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based AssessmentStatus unknownNCT04059081Phase 2
- Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
- Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaActive, not recruitingNCT03980171Phase 1/2
- A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaTerminatedNCT03866239Phase 1
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)Active, not recruitingNCT03824483Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
- Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
- A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1Status unknownNCT03679455Phase 2
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedNCT03467373Phase 1
- A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaActive, not recruitingNCT03410875Phase 2
- Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular LymphomaCompletedNCT03341520Phase 2
- Obinutuzumab in Marginal Zone LymphomaActive, not recruitingNCT03322865Phase 2
- Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2
- Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular RelapseTerminatedNCT03229382Phase 2
- Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell TransplantationTerminatedNCT03153514Phase 2
- Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's SyndromeCompletedNCT03113695Phase 1
- Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)WithdrawnNCT03086395Phase 2
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's LymphomaActive, not recruitingNCT03075696Phase 1/2
- Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
- Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCLCompletedNCT02987400Phase 2
- Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's MacroglobulinemiaCompletedNCT02962401Phase 2
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven MaintenanceCompletedNCT02896582Phase 2
- Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma PatientsCompletedNCT02877550Phase 1
- Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeActive, not recruitingNCT02846623Phase 2
- Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLCompletedNCT02758665Phase 2
- Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02750670Phase 2
- Combination of PCI-32765 With Obinutuzumab in Untreated Follicular LymphomaStatus unknownNCT02689869Phase 2
- Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.TerminatedNCT02670317Phase 2
- Phase II Trial GA101 Inbrutinib B CLLCompletedNCT02666898Phase 2
- Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02629809Phase 2
- Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.WithdrawnNCT02611908Phase 1
- A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting TransplantationCompletedNCT02586051Phase 1
- A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma PatientsCompletedNCT02558816Phase 1/2
- GOAL: GA101 Plus Pixantrone for Relapsed Aggressive LymphomaCompletedNCT02499003Phase 2
- A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT02453087Phase 1
- Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)CompletedNCT02445131Phase 2